Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors

Li Tan, Jun Wang, Junko Tanizaki, Zhifeng Huang, Amir R. Aref, Maria Rusan, Su Jie Zhu, Yiyun Zhang, Dalia Ercan, Rachel G. Liao, Marzia Capelletti, Wenjun Zhou, Wooyoung Hur, Namdoo Kim, Taebo Sim, Suzanne Gaudet, David A. Barbie, Jing Ruey Joanna Yeh, Cai Hong Yun, Peter S. Hammerman & 3 others Moosa Mohammadi, Pasi A. Jänne, Nathanael S. Gray

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

The human FGF receptors (FGFRs) play critical roles in various human cancers, and several FGFR inhibitors are currently under clinical investigation. Resistance usually results from selection for mutant kinases that are impervious to the action of the drug or from up-regulation of compensatory signaling pathways. Preclinical studies have demonstrated that resistance to FGFR inhibitors can be acquired through mutations in the FGFR gatekeeper residue, as clinically observed for FGFR4 in embryonal rhabdomyosarcoma and neuroendocrine breast carcinomas. Here we report on the use of a structure-based drug design to develop two selective, next-generation covalent FGFR inhibitors, the FGFR irreversible inhibitors 2 (FIIN-2) and 3 (FIIN-3). To our knowledge, FIIN-2 and FIIN-3 are the first inhibitors that can potently inhibit the proliferation of cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2, which confer resistance to first-generation clinical FGFR inhibitors such as NVP-BGJ398 and AZD4547. Because of the conformational flexibility of the reactive acrylamide substituent, FIIN-3 has the unprecedented ability to inhibit both the EGF receptor (EGFR) and FGFR covalently by targeting two distinct cysteine residues. We report the cocrystal structure of FGFR4 with FIIN-2, which unexpectedly exhibits a "DFG-out" covalent binding mode. The structural basis for dual FGFR and EGFR targeting by FIIN3 also is illustrated by crystal structures of FIIN-3 bound with FGFR4 V550L and EGFR L858R. These results have important implications for the design of covalent FGFR inhibitors that can overcome clinical resistance and provide the first example, to our knowledge, of a kinase inhibitor that covalently targets cysteines located in different positions within the ATP-binding pocket.

Original languageEnglish
Pages (from-to)E4869-E4877
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number45
DOIs
Publication statusPublished - 2014 Nov 11

Fingerprint

Fibroblast Growth Factor Receptors
Phosphotransferases
Epidermal Growth Factor Receptor
Cysteine
Embryonal Rhabdomyosarcoma
Neuroendocrine Carcinoma
Acrylamide
Drug Design
Up-Regulation
Adenosine Triphosphate
Cell Proliferation
Breast Neoplasms

Keywords

  • Cancer drug resistance
  • Drug discovery
  • Kinase inhibitor
  • Structure-based drug design

ASJC Scopus subject areas

  • General

Cite this

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. / Tan, Li; Wang, Jun; Tanizaki, Junko; Huang, Zhifeng; Aref, Amir R.; Rusan, Maria; Zhu, Su Jie; Zhang, Yiyun; Ercan, Dalia; Liao, Rachel G.; Capelletti, Marzia; Zhou, Wenjun; Hur, Wooyoung; Kim, Namdoo; Sim, Taebo; Gaudet, Suzanne; Barbie, David A.; Yeh, Jing Ruey Joanna; Yun, Cai Hong; Hammerman, Peter S.; Mohammadi, Moosa; Jänne, Pasi A.; Gray, Nathanael S.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 45, 11.11.2014, p. E4869-E4877.

Research output: Contribution to journalArticle

Tan, L, Wang, J, Tanizaki, J, Huang, Z, Aref, AR, Rusan, M, Zhu, SJ, Zhang, Y, Ercan, D, Liao, RG, Capelletti, M, Zhou, W, Hur, W, Kim, N, Sim, T, Gaudet, S, Barbie, DA, Yeh, JRJ, Yun, CH, Hammerman, PS, Mohammadi, M, Jänne, PA & Gray, NS 2014, 'Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors', Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 45, pp. E4869-E4877. https://doi.org/10.1073/pnas.1403438111
Tan, Li ; Wang, Jun ; Tanizaki, Junko ; Huang, Zhifeng ; Aref, Amir R. ; Rusan, Maria ; Zhu, Su Jie ; Zhang, Yiyun ; Ercan, Dalia ; Liao, Rachel G. ; Capelletti, Marzia ; Zhou, Wenjun ; Hur, Wooyoung ; Kim, Namdoo ; Sim, Taebo ; Gaudet, Suzanne ; Barbie, David A. ; Yeh, Jing Ruey Joanna ; Yun, Cai Hong ; Hammerman, Peter S. ; Mohammadi, Moosa ; Jänne, Pasi A. ; Gray, Nathanael S. / Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. In: Proceedings of the National Academy of Sciences of the United States of America. 2014 ; Vol. 111, No. 45. pp. E4869-E4877.
@article{2355565b7217493db7430f707d2e8a59,
title = "Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors",
abstract = "The human FGF receptors (FGFRs) play critical roles in various human cancers, and several FGFR inhibitors are currently under clinical investigation. Resistance usually results from selection for mutant kinases that are impervious to the action of the drug or from up-regulation of compensatory signaling pathways. Preclinical studies have demonstrated that resistance to FGFR inhibitors can be acquired through mutations in the FGFR gatekeeper residue, as clinically observed for FGFR4 in embryonal rhabdomyosarcoma and neuroendocrine breast carcinomas. Here we report on the use of a structure-based drug design to develop two selective, next-generation covalent FGFR inhibitors, the FGFR irreversible inhibitors 2 (FIIN-2) and 3 (FIIN-3). To our knowledge, FIIN-2 and FIIN-3 are the first inhibitors that can potently inhibit the proliferation of cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2, which confer resistance to first-generation clinical FGFR inhibitors such as NVP-BGJ398 and AZD4547. Because of the conformational flexibility of the reactive acrylamide substituent, FIIN-3 has the unprecedented ability to inhibit both the EGF receptor (EGFR) and FGFR covalently by targeting two distinct cysteine residues. We report the cocrystal structure of FGFR4 with FIIN-2, which unexpectedly exhibits a {"}DFG-out{"} covalent binding mode. The structural basis for dual FGFR and EGFR targeting by FIIN3 also is illustrated by crystal structures of FIIN-3 bound with FGFR4 V550L and EGFR L858R. These results have important implications for the design of covalent FGFR inhibitors that can overcome clinical resistance and provide the first example, to our knowledge, of a kinase inhibitor that covalently targets cysteines located in different positions within the ATP-binding pocket.",
keywords = "Cancer drug resistance, Drug discovery, Kinase inhibitor, Structure-based drug design",
author = "Li Tan and Jun Wang and Junko Tanizaki and Zhifeng Huang and Aref, {Amir R.} and Maria Rusan and Zhu, {Su Jie} and Yiyun Zhang and Dalia Ercan and Liao, {Rachel G.} and Marzia Capelletti and Wenjun Zhou and Wooyoung Hur and Namdoo Kim and Taebo Sim and Suzanne Gaudet and Barbie, {David A.} and Yeh, {Jing Ruey Joanna} and Yun, {Cai Hong} and Hammerman, {Peter S.} and Moosa Mohammadi and J{\"a}nne, {Pasi A.} and Gray, {Nathanael S.}",
year = "2014",
month = "11",
day = "11",
doi = "10.1073/pnas.1403438111",
language = "English",
volume = "111",
pages = "E4869--E4877",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "45",

}

TY - JOUR

T1 - Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors

AU - Tan, Li

AU - Wang, Jun

AU - Tanizaki, Junko

AU - Huang, Zhifeng

AU - Aref, Amir R.

AU - Rusan, Maria

AU - Zhu, Su Jie

AU - Zhang, Yiyun

AU - Ercan, Dalia

AU - Liao, Rachel G.

AU - Capelletti, Marzia

AU - Zhou, Wenjun

AU - Hur, Wooyoung

AU - Kim, Namdoo

AU - Sim, Taebo

AU - Gaudet, Suzanne

AU - Barbie, David A.

AU - Yeh, Jing Ruey Joanna

AU - Yun, Cai Hong

AU - Hammerman, Peter S.

AU - Mohammadi, Moosa

AU - Jänne, Pasi A.

AU - Gray, Nathanael S.

PY - 2014/11/11

Y1 - 2014/11/11

N2 - The human FGF receptors (FGFRs) play critical roles in various human cancers, and several FGFR inhibitors are currently under clinical investigation. Resistance usually results from selection for mutant kinases that are impervious to the action of the drug or from up-regulation of compensatory signaling pathways. Preclinical studies have demonstrated that resistance to FGFR inhibitors can be acquired through mutations in the FGFR gatekeeper residue, as clinically observed for FGFR4 in embryonal rhabdomyosarcoma and neuroendocrine breast carcinomas. Here we report on the use of a structure-based drug design to develop two selective, next-generation covalent FGFR inhibitors, the FGFR irreversible inhibitors 2 (FIIN-2) and 3 (FIIN-3). To our knowledge, FIIN-2 and FIIN-3 are the first inhibitors that can potently inhibit the proliferation of cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2, which confer resistance to first-generation clinical FGFR inhibitors such as NVP-BGJ398 and AZD4547. Because of the conformational flexibility of the reactive acrylamide substituent, FIIN-3 has the unprecedented ability to inhibit both the EGF receptor (EGFR) and FGFR covalently by targeting two distinct cysteine residues. We report the cocrystal structure of FGFR4 with FIIN-2, which unexpectedly exhibits a "DFG-out" covalent binding mode. The structural basis for dual FGFR and EGFR targeting by FIIN3 also is illustrated by crystal structures of FIIN-3 bound with FGFR4 V550L and EGFR L858R. These results have important implications for the design of covalent FGFR inhibitors that can overcome clinical resistance and provide the first example, to our knowledge, of a kinase inhibitor that covalently targets cysteines located in different positions within the ATP-binding pocket.

AB - The human FGF receptors (FGFRs) play critical roles in various human cancers, and several FGFR inhibitors are currently under clinical investigation. Resistance usually results from selection for mutant kinases that are impervious to the action of the drug or from up-regulation of compensatory signaling pathways. Preclinical studies have demonstrated that resistance to FGFR inhibitors can be acquired through mutations in the FGFR gatekeeper residue, as clinically observed for FGFR4 in embryonal rhabdomyosarcoma and neuroendocrine breast carcinomas. Here we report on the use of a structure-based drug design to develop two selective, next-generation covalent FGFR inhibitors, the FGFR irreversible inhibitors 2 (FIIN-2) and 3 (FIIN-3). To our knowledge, FIIN-2 and FIIN-3 are the first inhibitors that can potently inhibit the proliferation of cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2, which confer resistance to first-generation clinical FGFR inhibitors such as NVP-BGJ398 and AZD4547. Because of the conformational flexibility of the reactive acrylamide substituent, FIIN-3 has the unprecedented ability to inhibit both the EGF receptor (EGFR) and FGFR covalently by targeting two distinct cysteine residues. We report the cocrystal structure of FGFR4 with FIIN-2, which unexpectedly exhibits a "DFG-out" covalent binding mode. The structural basis for dual FGFR and EGFR targeting by FIIN3 also is illustrated by crystal structures of FIIN-3 bound with FGFR4 V550L and EGFR L858R. These results have important implications for the design of covalent FGFR inhibitors that can overcome clinical resistance and provide the first example, to our knowledge, of a kinase inhibitor that covalently targets cysteines located in different positions within the ATP-binding pocket.

KW - Cancer drug resistance

KW - Drug discovery

KW - Kinase inhibitor

KW - Structure-based drug design

UR - http://www.scopus.com/inward/record.url?scp=84909594628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909594628&partnerID=8YFLogxK

U2 - 10.1073/pnas.1403438111

DO - 10.1073/pnas.1403438111

M3 - Article

VL - 111

SP - E4869-E4877

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 45

ER -